Private Equity Fund MBK Acquires Japanese Arinamin Pharmaceutical for 2.9 Trillion Won

Domestic private equity firm MBK Partners is set to acquire Japan's renowned pharmaceutical company Arinamin Pharmaceutical for approximately 2.9 trillion KRW.

According to the financial investment industry on the 2nd, MBK Partners is scheduled to sign a stock purchase agreement on the 3rd to acquire Arinamin Pharmaceutical from the US private equity firm Blackstone for the stated amount.

Arinamin Pharmaceutical originated from Takeda Consumer Healthcare, a general pharmaceutical subsidiary of Japan's Takeda Pharmaceutical Company, and changed its name after being acquired by Blackstone in 2021.

It is well known for vitamins and fatigue-relief products, especially the 'Arinamin' vitamin medicine, which is sold domestically under the product name 'Actinum'.

This deal is interpreted as part of MBK Partners' strategy to strengthen its presence in the medical and healthcare sectors. Previously, MBK Partners acquired Osstem Implant, a domestic dental implant company, and Medit, an oral scanner company.

This content was produced with the assistance of AI translation services.